ClinicalTrials.gg
Status unknownNCT05762458AmmoxetineUpdated Mar 9, 2023

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

A Phase 2 interventional study of Ammoxetine and Placebo in Major Depressive Disorder (MDD), sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-03-09.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ammoxetine hydrochloride enteric-coated tablets in subjects with depression.

Read the detailed description

In this study, a randomized, double-blind, placebo-controlled multicenter study will be conducted to evaluate the efficacy and safety of different doses of Ammoxetine hydrochloride enteric coated tablets in the treatment of depression.

02

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • MDD
03

In context

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

This study's planned enrollment of 240 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 18 and 65 years (inclusive), no gender limitation;
  2. Subject has recurrent Major Depressive Disorder (MDD) as the primary diagnosis according to (DSM-5, 5th Edition), single episode or recurrent episodes (DSM-IV-TR criteria, classification code 296.2/296.3), without psychotic symptoms;
  3. Subjects with a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 26 at screening and baseline;
  4. Subjects with Clinical Global Impression Scale Disease Severity CGI-S severity score ≥ 4 at screening and baseline;
  5. A score of ≥2 on the first item (depressed mood) of the HAMD-17 scale at the screening and baseline;
  6. Male or female with fertility must agree to use effective method during the study and within 1 month after the end of the trial;
  7. Be able to read and understand the content of the and voluntarily sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with ≥ 25% reduction in MADRS score in the baseline period compared to the screening period;
  2. Subjects meet diagnostic criteria for other mental disorders (schizophrenia spectrum and other psychiatric disorders, bipolar and related disorders, anxiety disorders, obsessive-compulsive and related disorders, somatic symptoms and related disorders, etc.);
  3. Subjects are diagnosed as DSM-5 drug use disorder;
  4. depression (subjects who had previously used two different mechanisms of antidepressants and failed after receiving adequate treatment (at least 8 weeks);
  5. Organic mental disorders, such as depression caused by hypothyroidism;
  6. Depression caused by psychoactive substances or non-addictive substances;
  7. Subjects with other diseases or other types of mental disorders with depressive symptoms;
  8. Subjects assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) and those judged by the investigator to be at risk for suicide, or to have engaged in suicidal behavior within 6 months prior to screening;
  9. Allergic constitution (e.g. allergic to two or more drugs or to serotonin norepinephrine reuptake inhibitors (SNRIs));
  10. Previous history of malignant tumor;
  11. Previous history of elevated intraocular pressure or narrow angle glaucoma;
  12. Subjects suffered from other serious physical diseases, such as uncontrolled hypertension or unstable cardiovascular disease, serious liver disease, kidney disease, blood disease, endocrine disease, neurological disease, etc;
  13. Subjects with diseases that interfere with the absorption of oral medications, such as active bowel disease, partial or complete intestinal obstruction, chronic diarrhea, etc;
  14. Subjects who have used drugs or foods that alter the activity of liver enzymes (CYP2C19 and ) such as dexamethasone, rifampicin, omeprazole, etc., within 4 weeks prior to randomization;
  15. 12-lead system showed degree Ⅱ or Ш atrioventricular block, long syndrome or QTc > 450 ms (male) / 460 ms (female) at screening;
  16. Subjects discontinued use of a combination of drugs that prolong the QT interval prior to randomization, or drugs that can cause prolongation of the QT and may induce TdP for less than 5 half-lives of the drugs;
  17. In screening period, subjects with or AST 2 times higher than the upper limit of laboratory normal value; and abnormalities in 2 or more of the 5 indicators of thyroid function (TSH, FT3, FT4, TT3 or TT4 0.9 times below the lower limit of normal value or 1.1 times above the value);
  18. Subjects have used monoamine oxidase inhibitors within 2 weeks before randomization;
  19. Subjects discontinuing antipsychotics, antidepressants or mood stabilizers for less than 5 half-lives of the drug before randomization;
  20. Subjects who are using long half-life drugs (such as fluoxetine, long-acting antipsychotics, etc.);
  21. Subjects who have received electroconvulsive therapy (ECT), systematic psychotherapy (interpersonal relationship therapy, dynamic therapy, cognitive behavior therapy, etc.), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), phototherapy, etc. within 3 months before screening, or subjects who, in the judgment of the investigator, are currently in need of such treatment;
  22. Female subjects who are breastfeeding or have a positive pregnancy test during the screening period or during the study;
  23. Alcohol or drug dependence within 3 months before screening;
  24. Subjects who have participated in other clinical trials within 3 months before screening and are taking the test drug;
  25. Subjects who, in the opinion of the investigator, have any other condition that makes them unsuitable for participation in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Ammoxetine group-cohort 1

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.

    Drug: Ammoxetine · Drug: Placebo

  • Experimental
    Ammoxetine group-cohort 2

    The eligible subjects will receive Ammoxetine hydrochloride enteric-coated tablets plus placebo.

    Drug: Ammoxetine · Drug: Placebo

  • Placebo comparator
    Placebo group

    The eligible subjects will receive placebo to Ammoxetine.

    Drug: Placebo

Interventions

  • Ammoxetine hydrochloride enteric-coated tablets

  • DrugPlacebo

    placebo to Ammoxetine.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8)

    The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change score indicates improvement.

    Time frame: Baseline and week 8

Secondary outcomes

  1. Change from baseline in Hamilton Depression Scale (HAMD-17) at week 1, 2, 4, 6, 8

    Time frame: Baseline, week 1, 2, 4 ,6 and 8

  2. Change from baseline in Hamilton Anxiety Inventory (HAMA) scores at week 1, 2, 4, 6, 8

    Time frame: Baseline, week 1, 2, 4 ,6 and 8

  3. Change from baseline in CGI-S score at week 1, 2, 4, 6, 8

    Time frame: Baseline, week 1, 2, 4, 6 and 8

  4. Change from baseline in MADRS score at week 1, 2, 4, 6

    Time frame: baseline, week 1, 2 and 4, 6

  5. CGI-I scores at the end of 8 weeks of treatment at week 1, 2, 4, 6, 8

    Time frame: Baseline, week 1, 2, 4, 6 and 8

  6. The efficiency and remission of the MADRS score

    Effectiveness is defined as ≥ 50% reduction in MADRS score relative to baseline after treatment. Remission is defined as ≤ 10 MADRS score after treatment.

    Time frame: Baseline, Baseline, week 1, 2, 4, 6 and 8

  7. Efficacy and remission of HAMD-17 scores

    Effectiveness is defined as ≥50% reduction in HAMD-17 score relative to baseline after treatment. Remission is defined as HAMD-17 score ≤7 after treatment.

    Time frame: Baseline, week 1, 2, 4, 6 and 8

  8. The percentage of subjects with a MARDS score reduction ≥ 25%

    Time frame: Week 1 and 2

  9. Incidence of adverse events (AE)

    Time frame: Throughout the study period(From baseline to week 10)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2023; primary completion for May 2024, 14 months later.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 14 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2023
First posted
Mar 9, 2023
StartEst.
Feb 28, 2023
Primary completionEst.
May 15, 2024
CompletionEst.
Oct 15, 2024
Last update
Mar 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05762458
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Feb 28, 2023 (estimated)
Primary completion
May 15, 2024 (estimated)
Completion
Oct 15, 2024 (estimated)
Last update
Mar 9, 2023

Study contacts

Zhao Qian
Contact
zhaoq@mail.ecspc.com
+86-15893878757

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ammoxetine

Start the discussion